Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Free Cash Flow (2024 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Free Cash Flow for 2 consecutive years, with -$11.3 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 328.04% to -$11.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$51.6 million through Dec 2025, down 111.97% year-over-year, with the annual reading at -$51.6 million for FY2025, 111.97% down from the prior year.
  • Free Cash Flow hit -$11.3 million in Q4 2025 for Connect Biopharma Holdings, up from -$17.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$591000.0 in Q1 2024 to a low of -$17.4 million in Q3 2025.